Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 12 October 2022, 09:00 HKT/SGT
Share:
    

Source: Novotech Health Holdings Pte Ltd
Novotech India Recognised as "Best Workplaces for Women 2022" by Global Work Standards Authority

SYDNEY, AU, Oct 12, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, has again received "Best Workplace" certification by the leading workplace culture organization Great Place to Work Institute. Novotech's India team has received a Best Workplaces for Women 2022 recognition and listed in the Top 75 organisations in India recognised for excelling people practices, responsiveness to feedback and a culture of openness and diversity. Novotech also holds Great Place to Workplace recognition in Australia and Korea.

To identify India's Best Workplaces for Women 2022, Great Place to Work India studied 1122 organizations that had:
- Women employees constituting at least 10% of their workforce
- Women employees sharing at least 70% positive feedback on the Great Place to Work Trust Index Organizations that excelled in gender parity in representation

According to Great Place to Work India: "We have observed that the Best Workplaces have gone above and beyond to create and sustain aspirational organizations. We congratulate Novotech for being a role-model in India by fostering an equal and equitable workplace culture."

Novotech CEO Dr. John Moller said: "As a leading employer of women in India we are extremely pleased to be ranked among the top companies in India as a Best Workplaces for Women 2022. This is especially important for retaining and attracting top talent. This recognition demonstrates the importance of culture, diversity and work life balance as we strive to be one of the leading employers so we can deliver our world-class CRO services across India."

Novotech's Chief People Officer Angela Edwardson said: "We are delighted that Novotech India has been recognized as a leading employer for women. This is a real credit to our workplace culture and leadership that drives all our Asia Pacific and North American teams. Novotech attracts a high proportion of talented female employees, so we are extremely proud to have our workplace recognized using the criteria from the Great Place to Work Institute's Trust Index and the Gender Parity in Experience & Representation. Our continued focus on building a leading workplace means team members can balance their personal responsibilities with work during all stages of life."

According to Yooni Kim, Vice President, Global Clinical Services Novotech: "Employees are the most valuable assets of a company. Novotech is dedicated to improving our working environment and enhance employee health and wellbeing. We are more than grateful to receive this recognition."

Sridevi Gubbala, Manager Centralized Document Management Novotech said: "Novotech is a great place to work. It's wonderful to have flexibility at work because it helps me balance my work and personal life."

Vandana Jaising, Manager Project Support joined Novotech after an extended career break and said: "Women should consider coming back, even if it is has been a while. Before joining Novotech I took an eight-year career break, and now I'm glad Novotech had the confidence in me to say 'YES! You can do it!'"

Novotech has operations across Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late phase biotech clinical research.

Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.

About Novotech

Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contact

Media Contact
David James
E: communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427


Topic: Press release summary
Source: Novotech Health Holdings Pte Ltd

Sectors: Daily News, BioTech, Healthcare & Pharm, Local Biz, Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Novotech Health Holdings Pte Ltd
Feb 15, 2023 09:00 HKT/SGT
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
Feb 10, 2023 19:00 HKT/SGT
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
Feb 3, 2023 13:00 HKT/SGT
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
Jan 12, 2023 15:00 HKT/SGT
Novotech Acquires European CRO, Strengthens Global Operations
Jan 12, 2023 15:00 HKT/SGT
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
Dec 20, 2022 11:00 HKT/SGT
Novotech is Gold Sponsor at Biotech Showcase 2023
Dec 15, 2022 10:00 HKT/SGT
Data Shows 50% of New Trials Have Sites in Asia Pacific
Dec 6, 2022 11:00 HKT/SGT
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
Nov 11, 2022 17:00 HKT/SGT
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
Oct 25, 2022 18:00 HKT/SGT
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: